Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond E, Perez E, Bryant J, Suman V, et al. Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond E, Perez E, Bryant J, Suman V, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • From 1975 to 1996, new cancer drugs increased life expectancy of cancer patients by about one year, at an estimated cost of $3,000—well below the estimated value of a statistical…  
  • Pathogens cause around two million cancer cases worldwide each year. Ninety percent of these cases are attributable to Helicobacter pylori (H Pylori), hepatitis B virus (HBV), hepatitis C virus (HCV),…  
  • There are 3 million more cancer survivors today than there were a decade ago.  
  • The 5-year survival rate for localized breast cancer, is 98%–an 18% increase since the 1950s.  
  • A 2002 study found that image-guided percutaneous needle biopsies are between 3 and 7 times more cost-effective than open surgical biopsies, require a shorter procedure time, result in fewer infections,…